Drug Trial Radar · NCT05891158
A Study About Fazirsiran in People With and Without Liver Problems
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Oct 5, 2023
Primary completion
Sep 3, 2025
Study completion Sep 3, 2025
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn how the body processes fazirsiran (pharmacokinetics \[PK\]) in people with mild, moderate, or severe liver problems, compared to people with normal liver function. The study will include participants with liver scarring (cirrhosis) and mild, moderate, or severe liver problems, and participants with normal liver function. All participants will be given 1 injection of fazirsiran and will be followed up for 6 months after the fazirsiran injection.
Conditions
- Hepatic Impairment
Interventions
FazirsiranDrug
Fazirsiran SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of FazirsiranTime frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
- Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of FazirsiranTime frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
- Maximum Observed Plasma Concentration (Cmax) of FazirsiranTime frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 9, 24, 48, 360, 1368, 2160 and 4320 hours post-dose
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
CRU Hungary Kft
Kistarcsa, Hungary
Summit Clinical Research s.r.o.
Bratislava, Slovakia
Summit Clinical Research s.r.o.
Malacky, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.